The present invention relates to the detection of a protein associated with valvular heart disease of rheumatic origin. The mechanism of upregulation of the protein in human plasma in the patients suffering from valvular disease with rheumatic origin is demonstrated. The increased level of the protein in the urine samples of the rheumatic valve disease patients is also demonstrated. Estimation of this marker protein may be useful for diagnostic purpose for the patients with no clinical evidence for valvular disease. This protein can also be used for prognostic purpose after surgical intervention of the valvular disease of rheumatic origin. This protein can also be used for screening antifibrotic drug for the treatment of valvular heart disease.